Mechanisms of Propofol in Alleviating Neuropathic Pain by Inhibiting Microglial Pyroptosis in Spinal Cord Through the...

Area of Science:

• Neuroscience
• Anesthesiology
• Immunology

Background:

• Neuropathic pain (NP) is a debilitating condition often involving spinal cord inflammation.
• Microglial pyroptosis, a pro-inflammatory form of cell death, plays a significant role in NP pathogenesis.
• Propofol, a common anesthetic, has potential anti-inflammatory effects that warrant investigation in NP models.

Purpose of the Study:

• To elucidate the mechanism by which propofol affects microglial pyroptosis in the spinal cord during neuropathic pain.
• To investigate the role of the KDM3A/H3K9me2/WNT5A pathway in propofol's action on neuropathic pain.

Main Methods:

• A rat model of chronic constriction injury (CCI) was used to induce neuropathic pain.
• Behavioral tests (paw withdrawal mechanical threshold and thermal latency) were performed.
• Spinal cord tissue and BV2 microglial cells were analyzed for NLRP3, Iba1, KDM3A, H3K9me2, and WNT5A expression.
• In vitro experiments involved LPS stimulation and propofol treatment of BV2 cells.

Main Results:

• CCI induced neuropathic pain, characterized by reduced pain thresholds and increased spinal cord inflammation.
• KDM3A and WNT5A were upregulated in CCI, while propofol treatment reversed these changes.
• Propofol inhibited microglial pyroptosis, reduced KDM3A and WNT5A expression, and improved pain behaviors.
• KDM3A promoted WNT5A expression by suppressing H3K9me2, and this pathway was crucial for propofol's effects.

Conclusions:

• Propofol exerts a neuroprotective effect by inhibiting microglial pyroptosis in the spinal cord.
• The KDM3A/WNT5A pathway is a key mediator of propofol's anti-pyroptotic and analgesic effects in neuropathic pain.
• Targeting the KDM3A/WNT5A pathway may offer a novel therapeutic strategy for managing neuropathic pain.